Automated Cell Therapy Manufacturing Secures $1.1 Billion Across 34 Funding Rounds Led by Cellares and Ori Biotech

A $1.1 billion capital influx across 34 funding rounds is reshaping the GMP production model for cell therapies, with Cellares and Ori Biotech emerging as the dominant platforms, a signal that contract manufacturers and QA directors evaluating advanced therapy capacity will need to benchmark against closed, automated systems sooner than many current roadmaps anticipate.

The figures come from a Tracxn market report published in June 2026, which tracked investor activity across automated cell therapy manufacturing platforms. The concentration of capital in two lead companies suggests the sector is consolidating around scalable, platform-based approaches to CAR-T and broader advanced therapy production, rather than bespoke, operator-intensive workflows that have historically complicated process validation and batch reproducibility under 21 CFR Part 211 and equivalent GMP frameworks.

For plant heads and QA leads, the operational read is direct: automated closed-system platforms reduce contamination risk vectors, support sterility assurance by minimising open manipulations, and generate the structured process data that regulators increasingly expect under ICH Q10 pharmaceutical quality system principles. The funding trajectory implies these platforms are moving from early-adoption to infrastructure-level consideration within CDMOs and integrated manufacturers alike.

Ori Biotech's platform targets the bioprocessing instrumentation layer, while Cellares has positioned its Cell Shuttle system as an end-to-end GMP-ready manufacturing unit. Both approaches address the core tension in cell therapy scale-up: maintaining patient-specific lot integrity while achieving the throughput economics that make commercial supply viable. Regulatory agencies in the US and EU have signalled, through guidance and inspection posture, that automation and digital batch records are expected components of a credible cell therapy manufacturing submission.

Contract manufacturers assessing entry or expansion in the advanced therapy space will find the funding concentration instructive, capital is tracking toward platforms with demonstrated GMP compatibility and regulatory interaction history, not early-stage proof-of-concept systems.

The measurable checkpoint ahead is whether either platform converts its funding and regulatory milestones into commercial-scale GMP batch data sufficient to anchor a Biologics License Application or equivalent marketing authorisation submission within the next 24 months.

Source: Media4Growth via Indian Pharma Post, 19 June 2026.